Neuroprotective effects of a novel kynurenic acid analogue in a transgenic mouse model of Huntington’s disease

Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's disease

(2010) Cliona Stack et al.   FREE RADICAL BIOLOGY AND MEDICINE

Syntheses, Transformations and Pharmaceutical Applications of Kynurenic Acid Derivatives

(2009) F. Fulop et al.   CURRENT MEDICINAL CHEMISTRY

Kynurenate Derivative Attenuates the Nitroglycerin-Induced CamKIIα and CGRP Expression Changes

(2009) Enikő Vámos et al.   HEADACHE

Kynurenines in chronic neurodegenerative disorders: future therapeutic strategies

(2009) D. Zádori et al.   JOURNAL OF NEURAL TRANSMISSION

Neuroprotective effects of probenecid in a transgenic animal model of Huntington’s disease

(2009) Eniko Vamos et al.   JOURNAL OF NEURAL TRANSMISSION

In Vivo Evidence for NMDA Receptor-Mediated Excitotoxicity in a Murine Genetic Model of Huntington Disease

(2009) M. Y. Heng et al.   JOURNAL OF NEUROSCIENCE

l-kynurenine combined with probenecid and the novel synthetic kynurenic acid derivative attenuate nitroglycerin-induced nNOS in the rat caudal trigeminal nucleus

(2009) Enikő Vámos et al.   NEUROPHARMACOLOGY

Valproate ameliorates the survival and the motor performance in a transgenic mouse model of Huntington's disease

(2009) Dénes Zádori et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Of mice, rats and men: Revisiting the quinolinic acid hypothesis of Huntington's disease

(2009) Robert Schwarcz et al.   PROGRESS IN NEUROBIOLOGY

Tiagabine is neuroprotective in the N171-82Q and R6/2 mouse models of Huntington's disease

(2008) Naoki Masuda et al.   NEUROBIOLOGY OF DISEASE

Subtype-Specific Enhancement of NMDA Receptor Currents by Mutant Huntingtin

(2003) Nansheng Chen et al.   JOURNAL OF NEUROCHEMISTRY